By Elsa Ohlen
Novo Nordisk stock jumped Friday after the Danish drugmaker announced new data for a new weight-loss drug which appeared to be more efficient than its blockbuster drugs currently on the market, Ozempic and Wegovy.
U.S. traded shares in Novo Nordisk A/S were up 9.1% to $88.45 in premarket trading while Danish listed shares rose about 5%.
The mid-stage clinical trial showed patients that moved to the highest dosage of 20mg of the new medicine Amycretin lost 22% of their body weight in over 36 weeks.
Shares of Novo's main rival Eli Lilly fell 1.3%.
This is breaking news. Check back for more analysis soon.
Write to Elsa Ohlen at elsa.ohlen@barrons.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
January 24, 2025 06:05 ET (11:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.